IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan

2026 R&D Day presentation highlights include:LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. NASDAQ:IMNN, a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its IMNN-001 development program for women with newly diagn…